Source: Arteriosclerosis thrombosis and vascular biology. Unidade: FM
Subjects: COVID-19, ANTICOAGULANTES, HEMORRAGIA, FIBRINA
ABNT
HESS, Connie N et al. Novel Tissue Factor Inhibition for Thromboprophylaxis in COVID-19: Primary Results of the ASPEN-COVID-19 Trial. Arteriosclerosis thrombosis and vascular biology, v. 43, n. 8, p. 1572-1582, 2023Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/56014. Acesso em: 22 ago. 2024.APA
Hess, C. N., Hsia, J., Carroll, I. A., Nehler, M. R., Ruf, W., Morrow, D. A., et al. (2023). Novel Tissue Factor Inhibition for Thromboprophylaxis in COVID-19: Primary Results of the ASPEN-COVID-19 Trial. Arteriosclerosis thrombosis and vascular biology, 43( 8), 1572-1582. doi:10.1161/ATVBAHA.122.318748NLM
Hess CN, Hsia J, Carroll IA, Nehler MR, Ruf W, Morrow DA, Nicolau JC, Berwanger O, Szarek M, Capell WH. Novel Tissue Factor Inhibition for Thromboprophylaxis in COVID-19: Primary Results of the ASPEN-COVID-19 Trial [Internet]. Arteriosclerosis thrombosis and vascular biology. 2023 ; 43( 8): 1572-1582.[citado 2024 ago. 22 ] Available from: https://observatorio.fm.usp.br/handle/OPI/56014Vancouver
Hess CN, Hsia J, Carroll IA, Nehler MR, Ruf W, Morrow DA, Nicolau JC, Berwanger O, Szarek M, Capell WH. Novel Tissue Factor Inhibition for Thromboprophylaxis in COVID-19: Primary Results of the ASPEN-COVID-19 Trial [Internet]. Arteriosclerosis thrombosis and vascular biology. 2023 ; 43( 8): 1572-1582.[citado 2024 ago. 22 ] Available from: https://observatorio.fm.usp.br/handle/OPI/56014